Atlanta-The low-molecular-weight heparin enoxaparin improves outcomes compared with currently recommended therapy in patients with non-ST-segment elevation acute coronary syndromes (ACS) who are being treated with a glycoprotein (GP) IIb/IIIa inhibitor, said Shaun Goodman, MD.

Get the latest industry news, event updates, and more from Managed healthcare Executive.

Subscribe Now!

Outcomes in ACS: GP IIb/IIIa inhibitor plus LMWH superior to GPs plus unfractionated heparin

Newsletter